Firefly Neuroscience

Company Overview

Snapshot

Founded in January 2006 by Amir Geva, Firefly Neuroscience operates with 11–50 employees. The company has raised a total of $82.59 million across 11 funding rounds from 8 investors. In May 2025, Firefly Neuroscience expanded its database, IP portfolio, and commercial footprint through the acquisition of Evoke Neuroscience, Inc.

Business overview

Firefly Neuroscience is a Health Tech & Life Sciences company specializing in objective assessment of brain function through its Brain Network Analytics (BNA™) technology. The company's core product records and compares brain function to an FDA-cleared, age-matched database using AI and advanced signal processing. This technology enables clinicians and patients to make informed therapy and disease management decisions, track changes over time, and manage mental illnesses and cognitive disorders. Firefly Neuroscience serves the healthcare industry, operating within sectors such as Digital Healthcare and Medical Decision Support.

Strategic signal

In September 2025, Firefly Neuroscience partnered with HealingMaps to integrate its cognitive electrophysiology analytics into over 2,500 ketamine, psilocybin, and TMS clinics across North America. This collaboration signifies a strategic move to expand the reach and application of Firefly's BNA™ technology within the mental health treatment landscape, indicating a strong focus on commercial growth and market penetration for its diagnostic and monitoring solutions.

Company Intelligence Q&A

When did Firefly Neuroscience go public?

Firefly Neuroscience became public on NASDAQ in November 2021.

What was a significant recent acquisition by Firefly Neuroscience?

In May 2025, Firefly Neuroscience acquired Evoke Neuroscience, Inc., significantly expanding its database, IP portfolio, and commercial footprint.

What is Firefly Neuroscience's recent partnership with HealingMaps?

In September 2025, Firefly Neuroscience partnered with HealingMaps to offer its cognitive electrophysiology analytics to over 2,500 ketamine, psilocybin, and TMS clinics across North America.

What is Firefly Neuroscience's involvement in neuroscience drug development?

In September 2024, Firefly Neuroscience advanced its AI-driven BNA™ technology in neuroscience drug development after completing successful research collaborations with Takeda and Novartis.

What is Firefly Neuroscience's collaboration with Bright Minds Biosciences?

In October 2024, Firefly Neuroscience collaborated with Bright Minds Biosciences to analyze data from its positive Phase 1 study using its artificial intelligence, FDA-Cleared BNA™ technology.